The historical rank and industry rank for BioInvent International AB's Days Payable or its related term are showing as below:
LTS:0H22's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.1 * Ranked among companies with meaningful Days Payable only.
BioInvent International AB's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
BioInvent International AB Days Payable Related Terms
BioInvent International AB Days Payable Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0H22 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, BioInvent International AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioInvent International AB Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioInvent International AB's Days Payable distribution charts can be found below:
* The bar in red indicates where BioInvent International AB's Days Payable falls into.
BioInvent International AB Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioInvent International AB (LTS:0H22) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioInvent International AB and its competitors. According to the industry distribution chart, BioInvent International AB ranks #999999 out of 700 companies in the Biotechnology industry.
Is BioInvent International AB's Days Payable too high?
BioInvent International AB's current Days Payable is 0.00. Based on the distribution chart, BioInvent International AB ranks #999999 out of 700 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioInvent International AB has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioInvent International AB's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioInvent International AB ranks #999999 out of 700 companies for Days Payable. This places BioInvent International AB in the lower half of its industry. The industry median Days Payable is 113.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioInvent International AB and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioInvent International AB's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioInvent International AB stock overvalued right now?
Based on GuruFocus' analysis, BioInvent International AB (LTS:0H22) is currently considered Possible Value Trap. The stock's GF Value™ is kr50.45, compared to a current price of kr25.40 — trading 49.7% below its estimated fair value. The current Days Payable is 0.00. BioInvent International AB's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For BioInvent International AB (LTS:0H22), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioInvent International AB (LTS:0H22) Overvalued in 2026?
Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued.
The current stock price of kr25.40 is trading 49.7% below its estimated GF Value™ of kr50.45.
GuruFocus considers BioInvent International AB to be Possible Value Trap.
Key valuation signals for LTS:0H22:
Days Payable: 0.00
GF Value™: kr50.45 vs. price of kr25.40 (49.7% below fair value)
No single metric tells the full story. See the LTS:0H22 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
43GF Score
Get the complete analysis for LTS:0H22
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0H22 has been successfully added to your 
